Alto Neuroscience Execs Sued Over Rosy Drug Claims

By Lauren Berg · October 7, 2025, 10:53 PM EDT

An Alto Neuroscience investor claims CEO Amit Etkin and other directors overstated the efficacy of the psychiatric biotech company's lead drug candidate for treating major depressive disorder, according to a lawsuit...

To view the full article, register now.